1. Home
  2. LGO vs LIXT Comparison

LGO vs LIXT Comparison

Compare LGO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGO

Largo Inc.

HOLD

Current Price

$0.78

Market Cap

104.6M

Sector

N/A

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$6.79

Market Cap

107.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGO
LIXT
Founded
1988
2005
Country
Canada
United States
Employees
N/A
3
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.6M
107.6M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
LGO
LIXT
Price
$0.78
$6.79
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.25
N/A
AVG Volume (30 Days)
732.3K
271.0K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$50.56
N/A
Revenue Next Year
$59.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.68
52 Week High
$2.70
$7.51

Technical Indicators

Market Signals
Indicator
LGO
LIXT
Relative Strength Index (RSI) 33.83 59.65
Support Level N/A $3.82
Resistance Level $1.26 $7.50
Average True Range (ATR) 0.06 0.77
MACD 0.00 -0.09
Stochastic Oscillator 26.00 64.33

Price Performance

Historical Comparison
LGO
LIXT

About LGO Largo Inc.

Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.

Share on Social Networks: